Jacqualyn Fouse - Perrigo Company Independent Director

PRGO -- USA Stock  

USD 55.96  0.74  1.31%

  Director
Ms. Jacqualyn A. Fouse is Independent Director of the Company. Ms. Fouse has served as President, President, Global Hematology Oncology of Celgene, a leading global biopharmaceutical company, since August 2014, and previously served as Executive Vice President and Chief Financial Officer from September 2010 to August 2014. From 2007 until September 2010, she served as Chief Financial Officer for Bunge Ltd., a leading global agribusiness and food company. From 2002 to 2007, Ms. Fouse served as Senior Vice President, Chief Financial Officer and Corporationrationrate Strategy, at Alcon Laboratories, a NYSElisted eye care company. Prior to that, Ms. Fouse was Chief Financial Officer of Swissair Group in Switzerland from 2001 to 2002, and she was Group Treasurer of Nestle S.A. in Switzerland from 1999 to 2001. Ms. Fouse previously held various senior level financial positions in both the U.S. and Switzerland with both Alcon and Nestle from 1986 to 1999. She also held positions with LTV Aerospace and Defense and Celanese Chemical Company from 1983 to 1986. Ms. Fouse has served on the Board of Dicks Sporting Goods, a leading U.S. retailer of sporting goods and athletic apparel, since September 2010 and in May 2013 was appointed Chair of the Audit Committee. Ms. Fouse also serves on the Development Board and the College of Business Administration Advisory Board of the University of Texas at Arlington and on the Advisory Board of Texas Christian University
Age: 54  Director Since 2012      
353 1 709 4000  http://www.perrigo.com

Jacqualyn Fouse Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 2.34 % which means that it generated profit of $2.34 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 1.49 % meaning that it created $1.49 on every $100 dollars invested by stockholders.
The company currently holds 3.62B in liabilities with Debt to Equity (D/E) ratio of 63.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 1.88 which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Larry CordellOrigin Agritech Limited
2012
Arthur RyanRegeneron Pharmaceuticals
2003
Alan GarberVertex Pharmaceuticals Incorpor
2017
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Frank DAmelioZoetis
2016
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Willie ReedZoetis
2014
Min TangOrigin Agritech Limited
2009
Louise ParentZoetis
2013
George SingRegeneron Pharmaceuticals
1988
Michael BrownRegeneron Pharmaceuticals
1991
Michael TrimbleOrigin Agritech Limited
2006
Anupam PuriDr Reddys Laboratories Ltd
2002
Ashok GangulyDr Reddys Laboratories Ltd
2009
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Sridar IyengarDr Reddys Laboratories Ltd
2011
David GreenwayVertex Pharmaceuticals Incorpor
2017
Gregory NordenZoetis
2013
Yingqi XiaOrigin Agritech Limited
2010
William DoyleZoetis
2015

Entity Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Ronald Winowiecki, Acting CFO
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Thomas Farrington, Senior Vice President CIO
Herman Morris, Independent Director
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive VP, General Counsel and Secretary
Rolf Classon, Independent Director
Raymond Silcock, CFO
Shlomo Yanai, Independent Director Nominee
Jatin Shah, Senior Vice President Chief Scientific Officer
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Murray Kessler, President CEO, Director
Sharon Kochan, Executive VP and General Manager of International
Gary Kunkle, Lead Independent Director
Joseph Papa, Chairman and CEO
Marry Brlas, Independent Chairman of the Board
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
Bradley Joseph, IR Contact Officer
James Dillard, Executive Vice President Chief Scientific Officer
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Ronald Janish, Executive Vice President - Global Operations and Supply Chain
Uwe Rohrhoff, President CEO, Director

Stock Performance Indicators

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Currently Active Assets on Macroaxis

LC   
Purchased over 20 shares of
few hours ago
Traded for 15.09
MEIKX   
Purchased few shares of
few hours ago
Traded for 42.34
JPM   
Purchased few shares of
few hours ago
Traded for 119.16
OPK   
Purchased over 100 shares of
few hours ago
Traded for 2.27
MA   
Purchased one share of
few hours ago
Traded for 274.08
Additionally take a look at Your Equity Center. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.
Search macroaxis.com